Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced that it has added Gregory T.
Lucier to its Board of Directors, increasing the size of the Board from
seven to eight.
Mr. Lucier served as Chief Executive Officer and Chairman of the Board
of Life Technologies Corporation, a global biotechnology company, until
it was acquired by Thermo Fisher Scientific, Inc. in February 2014.
During Mr. Lucier’s 11 years at Life Technologies, he transformed the
company from a small start-up known as Invitrogen in 2003, through the
acquisition of Applied Biosystems in 2008, and into a global,
world-leading biotechnology firm that by 2014 had nearly $4 billion in
sales, industry-leading operating margins and operations in more than
160 countries. He achieved growth and increasing profitability at Life
Technologies through a commitment to significant investment in
innovation, the acquisition of complementary technologies, and a strong
focus on operational excellence.
Prior to Life Technologies, Mr. Lucier was a corporate officer at
General Electric Company, where he served in a variety of leadership
roles. During his distinguished career, Mr. Lucier has also served as a
Director of Carefusion Corporation from August 2009 to March 2015.
Currently, Mr. Lucier is serving as Chairman and Interim CEO of
NuVasive, Inc., a leading medical technology company focused on
transforming spine surgery with minimally disruptive, procedurally
integrated solutions.
“We are extremely excited to welcome Greg to our Board,” commented John
Chiminski, President and Chief Executive Officer of Catalent, Inc.
“Greg’s wealth of executive leadership experience and successful track
record in driving both organic and inorganic strategic growth will
enable him to be a strong contributor in guiding Catalent’s own
continued growth and in strengthening our leadership position.”
Mr. Lucier commented, “I am pleased to join the Catalent Board and
expect my experience in building and growing companies to complement the
Company’s ongoing strategic efforts. I look forward to working with
Catalent’s strong Board and experienced management team as they continue
to execute against their compelling market and industry opportunities.”
Mr. Lucier received his Master of Business Administration from Harvard
Graduate School of Business Administration; and his Bachelor of Science
Degree, with high distinction, in Industrial Engineering from
Pennsylvania State University.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs approximately
8,000 people, including over 1,000 scientists, at 30 facilities across 5
continents and in fiscal 2014 generated more than $1.8 billion in annual
revenue. Catalent is headquartered in Somerset, N.J.
More products. Better treatments. Reliably supplied.™
Investors:
Thomas Castellano, Catalent, Inc.
or
Jeremy Feffer, Bertner Advisors, LLC
732-537-6325
investors@catalent.com